AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
Previous Symbol
CUSIPN/A
Phone650-216-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio4.56
Quick Ratio4.50
Price-To-Earnings
Trailing P/E Ratio-2.32
Forward P/E Ratio-3.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.99 million
Price / Sales19.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.73) per share
Price / Book-3.49
Profitability
EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-1,952.41%
Return on EquityN/A
Return on Assets-62.70%
Miscellaneous
Employees41
Outstanding Shares61,910,000
Market Cap$167.15 million
OptionableOptionable
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. The specialty pharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $1.10 million. View AcelRx Pharmaceuticals' Earnings History.
When is AcelRx Pharmaceuticals' next earnings date?
What price target have analysts set for ACRX?
7 brokers have issued 12-month target prices for AcelRx Pharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $8.6667 in the next twelve months. This suggests a possible upside of 239.9% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.
What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.
What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?
Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (12/14/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post ACRX’s analyst day in NYC, we reiterate our Overweight rating and 12-month price target of $9. Despite Dsuvia approval on the large market opportunity ahead for the pain product, we believe the market continues to undervalue ACRX stock. The KOL’s in attendance today were very positive on their willingness to use Dsuvia in their respective emergency rooms and/or surgery centers, underscoring our positive thesis for Dsuvia’s prospects." (12/11/2018)
- 3. HC Wainwright analysts commented, "916-3963, Probability of approval Risk-adj value Full value Dsuvia – U.S. 100% $8.06 $8.06 Shares outstanding 61,907 Zalviso – EU 100% $0.15 $0.15 Current share price $4.27 Discount rate 12.5% Zalviso – U.S." (11/6/2018)
Has AcelRx Pharmaceuticals been receiving favorable news coverage?
News headlines about ACRX stock have been trending neutral recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next few days.
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include Eagle Pharmaceuticals (EGRX), Forty Seven (FTSV), CytomX Therapeutics (CTMX), Omeros (OMER), Rocket Pharmaceuticals (RCKT), Dynavax Technologies (DVAX), Urogen Pharma (URGN), Viking Therapeutics (VKTX), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), Collegium Pharmaceutical (COLL), Eidos Therapeutics (EIDX), Karyopharm Therapeutics (KPTI), Inflarx (IFRX) and AMAG Pharmaceuticals (AMAG).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Mr. Vincent J. Angotti, CEO & Director (Age 50)
- Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)
- Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 49)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
Who are AcelRx Pharmaceuticals' major shareholders?
AcelRx Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.37%), Vanguard Group Inc (3.37%), BlackRock Inc. (1.27%), Fosun International Ltd (0.77%), Renaissance Technologies LLC (0.69%) and Bridgeway Capital Management Inc. (0.56%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.
Which institutional investors are selling AcelRx Pharmaceuticals stock?
ACRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Renaissance Technologies LLC. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Badri N Dasu and Lawrence G Hamel. View Insider Buying and Selling for AcelRx Pharmaceuticals.
Which institutional investors are buying AcelRx Pharmaceuticals stock?
ACRX stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Monashee Investment Management LLC, Bridgeway Capital Management Inc., GSA Capital Partners LLP and Cornerstone Capital Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $2.55.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $167.15 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.
What is AcelRx Pharmaceuticals' official website?
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
